Anika Therapeutics amends Bank of America credit line to $50.0 million through 2031
Anika Therapeutics entered into a Fifth Amendment to its revolving credit agreement with Bank of America, N.A., extending the senior revolving line of credit to a $50.0 million facility maturing July 10, 2031. The company may request up to an additional $50.0 million in commitments, for a maximum of $100.0 million, subject to lender approval. The filing does not report any borrowings under the facility, and the amendment adds lender liens on substantially all assets and financial covenants that shareholders should note.
Key points
- Senior revolving line of credit of $50.0 million, maturing July 10, 2031, with an option for up to $100.0 million aggregate commitments
- Interest at SOFR plus 0.25% to 1.25%, based on the consolidated leverage ratio; commitment fee of 0.20% to 0.30% per annum on unused amounts
- Lenders have a first priority lien on substantially all assets, except certain intangible assets; covenants cover leverage and interest coverage ratios
- Amendment dated July 10, 2026; 8-K filed July 14, 2026 with Exhibit 10.1 attached
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.